ViaScint

N/A

Report date: 2025/12/01 17:16:40

Base Information

Drug NameViaScint

Drug Alias Name123I-phenylpentadecanoic acidIodophenylpentadecanoic acid I-123Iodofiltic acid I-123 - Medco Research

ClassificationRadiation-emitting products > Radioactive diagnostic agentDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Nuclides > Iodine > 123I +[4]

Mechanisms of ActionRadionuclide imaging enhancers

TargetsNot applicable

Therapy Area/IndicationsAcute Coronary Syndrome

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesKing Pharmaceuticals

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMolecular Insight Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsAcute Coronary Syndrome

Other Information

ATC CodeN/A